GlassScriptPhysician profile
Elizabeth A Bollinger
NPI 1861635609
$11,361.04
in general payments reported to CMS, 2019-2025
32 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $929 · 2021: $906 · 2022: $1,377 · 2023: $1,949 · 2024: $2,473 · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007 · Education: $25.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,007.23 |
| Education | $25.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,411.15 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,364.35 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $867.92 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $773.98 | 2022-2024 | Zeposia |
| Pfizer INC. | $672.39 | 2019-2025 | |
| Qol Medical, LLC | $458.16 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $351.33 | 2020-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $343.53 | 2020-2025 | Ocaliva |
| Janssen Biotech, INC. | $341.96 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $339.98 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $319.37 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $307.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $275.90 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $176.57 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $164.38 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $119.94 | 2021-2025 | Interstim, Gi Genius |
| Aimmune Therapeutics, INC. | $118.05 | 2025 | Zenpep, Vowst |
| Genzyme Corporation | $116.46 | 2022-2024 | |
| Boston Scientific Corporation | $103.84 | 2023 | Captivator II |
| Braintree Laboratories, INC. | $96.59 | 2020-2025 | Suflave, Sutab |
| Celltrion USA INC. | $95.86 | 2023-2025 | Vegzelma, Yuflyma |
| Lilly USA, LLC | $93.34 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $91.89 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $71.75 | 2021-2023 | Rebyota |
| Allergan, INC. | $69.67 | 2019-2020 | |
| Shionogi INC | $64.25 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $50.52 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $37.33 | 2025 | Wegovy |
| Evoke Pharma, INC. | $17.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.30 | 2022 | |
| Capsovision, INC. | $15.46 | 2023 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.25 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bollinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.